NOXXON Pharma
  • About
    • Management
    • Supervisory Board
    • Scientific Advisory Board
  • Pipeline
    • Pipeline
    • NOX-A12
    • NOX-E36
    • Collaborations
  • Scientific Approach
    • Tumor Microenvironment
    • Technology
    • Scientific Publications
  • Investors
    • NOXXON in brief
    • Press Releases
    • Documentation
    • Corporate Governance
    • NOXXON and the Market
  • Contact
    • Careers
  • french
  • linkedin
  • twitter

About NOXXON

NOXXON’s oncology-focused pipeline breaks the tumor protection barrier and blocks tumor repair by neutralizing chemokines in the tumor micro-environment (TME). NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. NOXXON’s lead program NOX-A12 has delivered final top-line data from a combination trial with an anti-PD-1 immuno-oncology checkpoint inhibitor in metastatic colorectal and pancreatic cancer patients published at the ESMO conference in September 2020; based on the trial results including overall survival and safety profile further studies are being planned in pancreatic cancer. The combination of NOX-A12 and radiotherapy has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. A trial of NOX-A12 in combination with radiotherapy in newly diagnosed brain cancer patients who will not benefit from standard chemotherapy has delivered preliminary data from the first cohort showing consistent tumor reductions. The company’s second clinical-stage asset, NOX-E36 is a TME asset targeting the innate immune system and is planned to go back into the clinic in 2021. NOXXON plans to develop NOX-E36 in patients with solid tumors.

 

• Download the latest update report on NOXXON by Aurgalys
➥ See all reports on NOXXON here

 

Press Release

Berlin, Germany

2021, February 15
06:00 p.m.

NOXXON enrolls first patient in the high dose cohort of trial combining NOX-A12 with radiotherapy in newly diagnosed brain cancer

2021, February 08
06:00 p.m.

NOXXON appoints leading pancreatic cancer experts to Scientific Advisory Board

2021, February 01
06:00 p.m.

NOXXON appoints experienced cancer drug developer Dr. Jose Saro as chair of Scientific Advisory Board


Events

European Life Sciences CEO Forum

Aram Mangasarian
March 10-12, digital event


* Spiegelmer® is a registered trademark of NOXXON Pharma

Imprint | Disclaimer | Privacy Policy |


© NOXXON Pharma 2021

Usage of Cookies

We use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about our use of cookies can be found in our privacy policy. If you continue to use this website we will assume that you agree with the usage of cookies. You can prevent cookies from being installed or delete them from your computer. How this works, is explained in our privacy policy.

You have declined cookies. This decision can be reversed.

You have allowed cookies to be placed on your computer.

Usage of Cookies

We use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about our use of cookies can be found in our privacy policy. If you continue to use this website we will assume that you agree with the usage of cookies. You can prevent cookies from being installed or delete them from your computer. How this works, is explained in our privacy policy.